Lantheus Holdings Inc banner

Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 82.82 USD -0.07% Market Closed
Market Cap: $5.4B

P/B

4.9
Current
13%
Cheaper
vs 3-y average of 5.6

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
4.9
=
Market Cap
$4.9B
/
Total Equity
$1.1B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
4.9
=
Market Cap
$4.9B
/
Total Equity
$1.1B

Valuation Scenarios

Lantheus Holdings Inc is trading below its 3-year average

If P/B returns to its 3-Year Average (5.6), the stock would be worth $94.97 (15% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-49%
Maximum Upside
+15%
Average Downside
14%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 4.9 $82.82
0%
3-Year Average 5.6 $94.97
+15%
5-Year Average 5.6 $94.97
+15%
Industry Average 3.1 $52.67
-36%
Country Average 2.5 $42.42
-49%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
US
Lantheus Holdings Inc
NASDAQ:LNTH
5.3B USD 4.9 22.9
US
Medline Inc
NASDAQ:MDLN
60.7B USD 0 0
JP
Hoya Corp
TSE:7741
9.6T JPY 9.4 38.5
CH
Alcon AG
SIX:ALC
29.4B CHF 1.7 37.7
DK
Coloplast A/S
CSE:COLO B
95.4B DKK 6.9 23.8
US
Align Technology Inc
NASDAQ:ALGN
13.6B USD 3.4 33.2
UK
ConvaTec Group PLC
LSE:CTEC
4.4B GBP 3.8 33.2
CA
Bausch + Lomb Corp
NYSE:BLCO
5.6B USD 0.9 -15.5
JP
Asahi Intecc Co Ltd
TSE:7747
880.1B JPY 5.6 49.8
KR
HLB Inc
KOSDAQ:028300
8T KRW 19.2 -36.4
CN
Intco Medical Technology Co Ltd
SZSE:300677
36.4B CNY 2 21.4
P/E Multiple
Earnings Growth PEG
US
Lantheus Holdings Inc
NASDAQ:LNTH
Average P/E: 32.5
22.9
30%
0.8
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.5
15%
2.6
CH
Alcon AG
SIX:ALC
37.7
32%
1.2
DK
Coloplast A/S
CSE:COLO B
23.8
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
33.2
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
33.2
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
49.8
40%
1.2
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.4 N/A N/A
CN
Intco Medical Technology Co Ltd
SZSE:300677
21.4
12%
1.8

Market Distribution

Higher than 70% of companies in the United States of America
Percentile
70th
Based on 10 946 companies
70th percentile
4.9
Low
0 — 1.5
Typical Range
1.5 — 4.8
High
4.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.5
Median 2.5
70th Percentile 4.8
Max 147 580.5

Lantheus Holdings Inc
Glance View

Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.

LNTH Intrinsic Value
89.74 USD
Undervaluation 8%
Intrinsic Value
Price $82.82
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett